儿童与成人肺动脉高压特点比较ppt课件_第1页
儿童与成人肺动脉高压特点比较ppt课件_第2页
儿童与成人肺动脉高压特点比较ppt课件_第3页
儿童与成人肺动脉高压特点比较ppt课件_第4页
儿童与成人肺动脉高压特点比较ppt课件_第5页
已阅读5页,还剩33页未读, 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

1、儿童与成人肺动脉高压特点比较吴炳祥哈尔滨医科大学附属第一医院PAH的定义PAH流行病学及自然病程PAH的病理改动PAH的临床表现PAH的诊断流程PAH的治疗及预后主要内容肺动脉高压的定义Rich S,etal.Primary pulmonary hypertension.A national prospective study.Ann Intern Med 1987;107:216-223.成人:在海平面形状下,静息时,右心导管检查肺 动脉平均压(mPAP) 25mmHg,肺毛细血管楔压(PCWP)15mmHg,且肺血管阻力(PVR) 3WU.Barst RJ,etal.Pulmonary A

2、rterial Hypertension:a comparison between between children and adults.Eur Respir.2019,37:665-677.婴儿:平均肺动脉压/平均体循环动脉压,或肺动脉收缩压/体循环动脉收缩压0.4儿童患者:APAH-CHD,IPAH/HPAH高发成人患者:APAH-CTD那么相对较常见.CHD-PAHThere is a heterogeneity in the nature of CHD-PAH,with some patients developing irreversible disease in the firs

3、t year of life and others remaining free of symptoms untill their second or third decade, or even later.IPAH/HPAHThe natural history of untreated IPAH/HPAH is most often rapidly progressive and fatal.Sheila G etal,Assessment of endpoint in pediatric population:congenital heart disease and idiopathic

4、 pulmonary arterial hypertension.Curr Opin Pulm Med 16(Suppl1):S35-S41.流行病学及自然病程流行病学及自然病程病理学 The presenting symptoms are usually more severe in children , with syncopal episodes occuring more frequently than in adults,and a rate of disease progression that is typically faster. 临床表现劳力性呼吸困难,乏力,晕厥,胸痛,右

5、心功能不全伴外周水肿.治疗原发病与肺高压严重程度不匹配病史/病症/体征疑心肺高压ECG,胸片,超声心动图,肺功能,HRCT确诊为第二或第三大类肺通气灌注扫描与肺高压严重程度匹配节段性灌注缺损PAH能够,建议RHC检查CTEPHPVOD/PCHmPAP25mmHg,PCWP15mmHg其它缘由是是是否否否是诊断流程是儿童患者对病症表述不准确,多需求家长的察看 儿童患者运动量大,且患上呼吸道感染的时机高,故儿童在疾病的早期即可出现相应的病症,有利于早期诊断.儿童IPAH/HPAH,APAH-CHD患者在诊断时,其心功能分级和血流动力学目的好于成人.儿童患者的特殊性严重程度评价严重程度评价1. 临床

6、特点 WHO心功能分级的评价对成人及大龄儿童适用,但不适宜运用于新生儿或低龄儿童. uTime to clinical worsening is a reliable and appropriate means of assessing disease progression. (though not adopted in children)uUsing clinical worsening as an endpoint in children could be particularly helpful because of the faster rate of disease progres

7、sion in many children with IPAH.Sheila G etal,Assessment of endpoint in pediatric population:congenital heart disease and idiopathic pulmonary arterial hypertension.Curr Opin Pulm Med 16(Suppl1):S35-S41.2. 运动耐量六分钟步行实验(6MWT):实验过程不适宜评价儿童患者,实验所得数据不可靠.心-肺吸氧运动实验(CPET):适用于成人和7-8岁以上的儿童.有助于发如今休憩时肺动脉压力正常,而运动

8、后那么出现异常的患者.CPET,in contrast to the 6-minute walk test,may be particularly relevant to identify those children who have an exaggerated response of the pulmonary vascular bed to exercise and appear to have good exercise capacity with normal activities of daily living,but have a history of syncopal epi

9、sodes with over-exertion or in response to mild hypoventilation with sleepRosenzweig EB,etal.Pulmonary arterial hypertension in children.Pediatr Pulmonol 2019;38:2-22.3.生化标志物NT-proBNP , BNP , 血尿酸,C反响蛋白等目的也可运用于儿童病情严重程度及预后的评价.Lower NT-proBNP and BNP concentrations have been reported in children compar

10、ed with adults,consistent with right heart failure being less frequent in children as compared with adult patients.Lammer AE,etal.Prognostic value of B-type natriuretic peptide in children with pulmonary arterial hypertension.Int J Cardiol 2021;:21-26由于非侵入性评价目的在儿童患者中难以执行,所得结果可信度差,因此,血流动力学目的依然作为儿童患者评

11、价疾病严重程度及疗效的金规范.Barst RJ,etal.Pulmonary Arterial Hypertension:a comparison between between children and adults.Eur Respir.2019,37:665-677.治治 疗疗p普通治疗p支持治疗p靶向药物治疗p其它普通治疗支持治疗儿童患者抗凝风险评价有争议,可在特殊情况时思索抗凝,如右心功能不全,高凝形状,中心静脉置管等.靶向药物治疗1.钙拮抗剂 只需肺血管扩张实验阳性者才干从CCBs治疗中获益.It is important to remember that vasoreactive

12、 patients require constant re-evaluation, as reactivity can be lost at any time.Sheila G etal,Assessment of endpoint in pediatric population:congenital heart disease and idiopathic pulmonary arterial hypertension.Curr Opin Pulm Med 16(Suppl1):S35-S41.阳性规范:mPAP下降幅度超越10mmHg并且绝对 值40mmHg,CO添加或至少不变.(儿童能否

13、适用有争议)In children with IPAH,the probality of having a positive response to the pulmonary vasoractivity test appears to be age dependent,with the youngest having the greatest likelihood of pulmonary vasodilation;the percentage of responders in children is 30-40% compared with 10-15% in adults.Barst R

14、J,etal.Vasodilator therapy for primary pulmonary hypertension in children.Circulation 2019;99:1197-1208.血管舒张实验阳性率Yung D,etal.Outcomes in Children With Idiopathic Pulmonary Arterial Hypertension.Circulation 2019:110:660-665.儿童儿童Long-term CCB responders represented 54% of acute responders and 6.8% (95

15、% CI, 4.7% to 8.9%) of the patient sample.Sitbon O,etal.Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension . Circulation. 2019;111:3105-3111.成人成人2.前列环素类 依前列醇(Epoprostenol) 伊洛前列素(Iloprost) 曲前列环素(Treprostinil) 贝前列环素(Beraprost)伊洛前列素,曲前列环素,贝前列环素在儿童患者运用相关报道较少.u依前列醇(Epopros

16、tenol)在儿童及成人患者中均有较好疗效,但在儿童患者中其最正确剂量常较高.由于其用药途径特殊,故在儿童患者中运用不便.Epoprostenol has also been used in children of all ages with similar safety and efficacy as shown in adult ptients. However,optimal dosing in children is frequently higher in a nanograms per kilogram per minute basis.Barst R. How has epopr

17、ostenol changed the outcome for patients with pulmonary arterial hypertension?Int J Clin.PractSuppl.2019,64(168):23-32.成人成人儿童儿童一年生存率80-91%94%三年生存率49-65%88%五年生存率47-55%81%Yung D,etal.Outcomes in children with idiopathic pulmonary arterial hypertension.Circulation 2019;110:660-665.依前列醇依前列醇3.内皮素受体拮抗剂 波生

18、坦(bosentan) 塞他生坦(sitaxsentan) 安贝生坦(Ambrisentan)塞他生坦,安贝生坦在儿童患者运用相关报道较少.u波生坦在儿童及成人中均有较好疗效,可改善WHO心功能分级和血流动力学等目的.Gatzoulis MA,etal. Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease.Eur Respir Rev.2021,18(113):154-61.Ivy DD, etal.Long-Term Outcomes in Childre

19、n With Pulmonary Arterial Hypertension Treated With Bosentan in Real-World Clinical Settings.Am J Cardiol. 2019 Nov 1;106(9):1332-8. 波生坦(儿童) 波生坦(成人) Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension Eur Heart J. 2019 Mar;27(5):589-95. 4. PDE5抑制剂西地那非(sil

20、denafil) 伐地那非(vardenafil) 他达那非(tadalafil) 伐地那非,他达那非在儿童患者运用相关报道较少.西地那非在儿童及成人中均有较好疗效,可改善血流动力学,提高运动耐量.Xu XQ,etal.The efficacy and safety of sildenafil in Chinese patients with pulmonary arterial hypertension. Hypertension Reseach(2021)32,911-915.西地那非(成人)Oliveira EC,etal.Sildenafil in the management of

21、idiopathic pulmonary arterial hypertension in children and adolescents.J Pediatr,2019;81(5):390-4.西地那非(儿童)靶向药物治疗后的生存率Haworth SG,etal.Treatment and survival in children with pulmonary arterial hypertension:the UK Pulmonary Hypertension Service for children 2019-2019.Heart 2021;95:312-317.药物药物剂量剂量给药途径

22、给药途径适应症适应症副作用副作用氧气保持SaO2为94%吸入低氧血症儿童用量过多安全性差NO2-20ppm吸入NICU,PICU低血压CCB(硝苯地平)0.2mg/kg ,每8小时口服IPAH低血压5-磷酸二酯酶抑制剂(西地那非)0.25mg/kg,每6小时口服新生儿慢性肺疾病,艾森曼格综合症低血压,视觉障碍内皮素受体拮抗剂(波生坦)15-125mg(按体重),每12小时口服IPAH,艾森曼格综合症低血压,肝功损害前列环素(依前列醇)2-60ng/kg/min静脉注射艾森曼格综合症低血压,出血前列环素(伊洛前列环素)5ug,每2-3小时,逐渐增至最大耐受量吸入慢性肺部疾病,艾森曼格综合症低血压

23、儿童患者肺动脉高压治疗药物儿童患者肺动脉高压治疗药物Robert T.Etiology,Diagnosis,and Pharmacologic Treatment of Pediatric Pulmonary Hypertension.Pediatr Drugs,2021,11(2):115-128肺动脉高压支持疗法:抗凝,吸氧,改善生活习惯血管舒张实验阳性阴性CCB稳定性WHO/不稳定性WHO/波生坦,前列环素类依前列醇继续监测病症性WHO,进展性呼吸困难,难治性心衰,晕厥(CCB阳性患者:治疗数月后对CCB反响性下降)结合药物治疗移植房间隔造瘘术治疗流程National Pulmonary

24、 Hypertension Centres of the UK and Ireland.Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland.Heart 2019;94(Supp1):i1-i41.未经治疗的儿童IPAH患者预后比成人差.在靶向治疗药物运用之前儿童PAH患者中位生存时间只需10个月,而成人为2.8年. (DAlonzo GE,etal.Survival in patients with primary hypertens

25、ion.Ann Intern Med 1991;115:343-349)靶向药物运用后生存率显著提高.预 后美国国立卫生研讨院(NIH)对194例特发性PAH 患者的统计,平均生存期仅为2.8年, 1年、3年和5年的生存率分别为68、48和34.IPAHAPAH一年生存率85.6%92.3%三年生存率79.9%83.8%五年生存率71.9%56.9%Haworth SG,etal.Treatment and survival in children with pulmonary arterial hypertension:the UK Pulmonary Hypertension Service for children 2019-2019.Heart 2021;95:312-317.儿童靶向药物治疗后IPAH,APAH一年,三年,五年总体生存率分别为90.5%,82.8%,和64.2%. IPAH和APAH生

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论